These in vivo data add to the support for testing of the EGFR and CDK4/6 combination in patients with EGFR-positive ESCC as well as for the potential efficacy of the EGFR/MEK doublets. The gene discussed is MAP2K7; the disease is esophageal squamous cell carcinoma.